Michelle Fang

Vice President, Legal Affairs at RemeGen Biosciences

Michelle Fang has a diverse work experience. Michelle is currently working at RemeGen as the Senior Director of International Legal Affairs since October 2021. Prior to this role, they held the position of Director of International Legal Affairs at RemeGen from May 2019 to October 2021. Michelle also served as the Vice President of Legal Affairs at RemeGen Biosciences starting from July 2020. Before joining RemeGen, Michelle worked at Fenwick & West as a Corporate Associate from September 2017 to May 2019. Michelle also had a summer associate position at Fenwick & West in 2016. Michelle has experience in the legal field, having worked as a Judicial Extern at the U.S. District Court for the Northern District of California in 2015. Prior to their legal career, they served as a JusticeCorps Member at AmeriCorps, where they managed over 500 legal cases at the Inglewood Superior Courthouse and provided assistance to pro se litigants. Michelle also worked as a Senior Executive Clerk at UCLA Anderson School of Management.

Michelle Fang received their Bachelor of Arts (B.A.) in Political Science from UCLA in 2012. Michelle then went on to obtain their Juris Doctor (J.D.) from the University of California, Los Angeles - School of Law in 2017.

Location

San Francisco, United States

Links

Previous companies


Org chart


Teams


Offices


RemeGen Biosciences

1 followers

RemeGen is a global biopharmaceutical company, focusing on the discovery, development and commercialization of novel biologics for the treatment of autoimmune, oncology and ophthalmic diseases with significant unmet medical needs. RemeGen Biosciences, a wholly owned subsidiary of RemeGen, is based in South San Francisco, California, the birthplace of biotechnology and in Maryland. Our vision is to create the first-in-class and/or best-in-class biotherapeutics with innovative target discovery strategies, advanced molecule design and protein engineering platforms. Our passion is to serve patients with more effective therapies in a timely manner.